AKBA News and Press, Akebia Therapeutics Inc. From 08/04/25

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a post-marketing study to identify additional potential ...

2025-07-31 21:35:00 ET Key Takeaways Read the full article on Seeking Alpha For further details see: Franklin Biotechnology Discovery Fund Q2 2025 Commentary

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host...

2025-07-12 11:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Wall Street Week Ahead, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings re...

2025-07-11 15:00:55 ET More on the markets A Market-Topping Volatility Trade Is Sending A Warning Message, Again Debt Ceiling Increase Will Allow U.S. Treasury To Resume Borrowing If You Were Buying In April, You Should Be Trimming In July Trump slaps 35% lev...

CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fire...

2025-06-18 10:31:31 ET Akebia Therapeutics, Inc. (NASDAQ: AKBA) is the focus of IBN’s latest stock spotlight. The company’s shares have moved 1.43% on the day to $3.55. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercializa...

2025-06-07 23:36:42 ET ... Read the full article on Seeking Alpha For further details see: Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026

2025-06-06 17:26:17 ET ... Read the full article on Seeking Alpha For further details see: Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside

2025-06-04 16:23:13 ET Summary Vafseo's strong US launch and outperforming Q1 revenues signal robust demand and even potential for eventual blockbuster status, but near-term profitability remains uncertain. Auryxia's patent expiry and declining sales will pressure Akebia's financi...